Adamas Announces New Employment Inducement Grant
Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) has granted restricted stock units to two new employees, allowing them to acquire a total of 57,000 shares of common stock. These units will vest over three years and were issued under the 2016 Inducement Plan approved by the board in March 2016. This initiative aims to attract talent to the company, which is dedicated to innovating therapies for neurological diseases.
- Granting of 57,000 restricted stock units could enhance employee retention and motivation.
- Under the 2016 Inducement Plan, the company demonstrates commitment to attracting talent.
- None.
Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the compensation committee of the company’s board of directors granted two new employees restricted stock units to acquire 57,000 shares of the company’s common stock. The restricted stock units vest over three years and were granted pursuant to the Adamas Pharmaceuticals, Inc. 2016 Inducement Plan, which was approved by the company's board of directors in March 2016 under Rule 5653(c)(4) of the Nasdaq Global Market for equity grants to induce new employees to enter into employment with the company.
About Adamas Pharmaceuticals, Inc.
At Adamas our vision is clear – to deliver innovative medicines that reduce the burden of neurological diseases on patients, caregivers and society. We are a fully integrated company focused on growing a portfolio of therapies to address a range of neurological diseases.
Source: Adamas Pharmaceuticals, Inc.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210305005009/en/
FAQ
What is the latest press release from Adamas Pharmaceuticals regarding employee compensation?
When will the restricted stock units for ADMS employees vest?
What plan is associated with the restricted stock units granted by Adamas Pharmaceuticals?
What is the purpose of granting restricted stock units at Adamas Pharmaceuticals?
